Clinical trial
A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo
NCT02598388 is registered in ClinicalTrials.gov with Janssen Vaccines & Prevention B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 10, 2015
- Completion date
- December 12, 2018
- Enrollment
- 578 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.